Hepatitis A | Pediatric: Havrix® (GlaxoSmithKline); 720 EU VAQTA® (Merck); 25 U | IM; 0.5 mL | Primary series: 2 doses, 6–18 mo apart Booster: currently not recommended | Children ≥1 y old | Inactivated vaccine. Lifelong protection is likely |
| Adult: Havrix® (GlaxoSmithKline); 1440 EU VAQTA® (Merck); 50 U | IM; 1.0 mL | Primary series: 2 doses, 6–18 mo apart Booster: currently not recommended | Adults ≥19 y old | Inactivated vaccine. Lifelong protection is likely |
Hepatitis A and B | Twinrix® (GlaxoSmithKline) | IM; 1.0 mL | Primary series: 3 doses at 0, 1, and 6 mo Accelerated schedule: 0, 7, and 21 d; fourth dose 12 mo later Boosters: not needed | Adults ≥18 y old | Inactivated vaccine. Lifelong protection is likely. Accelerated schedule is as effective |
Immunoglobulin, human | Injectable | IM | Travel <3 mo duration: 0.02 mL/kg body weight. Travel >3 mo duration: 0.06 mL/kg body weight every 4–6 mo | Infants <1 y of age | Passive immunizations against hepatitis A. Will require delay of measles and varicella vaccinations (at least 3 mo) |
Japanese encephalitis virus | Inactivated | SC; 1.0 mL | Primary series: 3 doses at days 0, 7, and 30. Booster: 1 dose at 24 mo interval | Travel to high-risk areas; prolonged stays | Allergic reactions can be life-threatening. Persons need to be observed for 30 min after each dose and the series must be completed ≥10 d before departure |
Meningococcal | Quadrivalent: A, C, Y, W135 | SC; 0.5 mL | Primary series: single dose Booster: 5 y in persons ≥4 y old; 2–3 y in children 2–4 y old | ≥2 y old | Required for entry to Saudi Arabia during the Hajj |
Meningococcal conjugate | Quadrivalent: A, C, Y, W135 | IM; 0.5 mL | Primary series: single dose Booster: unknown | Not previously vaccinated ≥11–12 y old | Required for entry to Saudi Arabia during the Hajj |
Rabies | Inactivated | IM; 1.0 mL | Preexposure series: 3 doses at days 0, 7, and 21 or 28. Booster: depends on risk category and serological testing. Postexposure: rabies immune globulin; day 0; vaccines at days 0, 3, 7, 14, and 28 | | Consider for young travelers planning prolonged stays; especially away from large urban centers with adequate medical care systems and airport |
Typhoid fever | Live-attenuated Ty21a1 | Oral | 1 capsule every-other-day for 4 doses. Boosters: every 5 y | Persons ≥6 y old | If series sequence not completed, all 4 doses need to be repeated. Contraindicated in immunocompromised hosts. Cannot be taken with hot beverage. Person must not be taking antibiotics |
| Injectable Polysaccharide Vi antigen | IM; 0.5 mL | Primary series: one dose. Booster: every 2 y | Persons ≥2 y old | Inactivated vaccine |
Yellow fever | Live injectable | SC; 0.5 mL | Primary series: one dose. Dose must be given at least 10 d before arrival to risk area. Booster: every 10 y. | ≥9 mo old. | Contraindicated in immunocompromised hosts. Avoid in pregnancy, unless high-risk travel cannot be avoided. Contraindicated in infants <4 mo of age. Avoid in persons with thymus disorders. Caution in persons ≥60 y old (high risk for vaccine-related infection). Requires official certificate of vaccination |